Sagimet Biosciences Inc. Series A Common Stock
SGMTSagimet Biosciences Inc. Series A (SGMT) is a biotechnology company focused on developing innovative therapies for metabolic and fibrotic diseases. The company specializes in targeting liver and metabolic disorders through novel small molecule drugs, aiming to address unmet medical needs in these areas.
Company News
Sagimet Biosciences reported positive Phase 3 clinical trial results for denifanstat in treating moderate to severe acne in China, with the drug meeting all primary and secondary endpoints and being well-tolerated.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Stifel cut the price target for Spire Global, Inc. (NYSE:SPIR) from $24 to $20. Stifel analyst Erik Rasmussen maintained a Buy rating. Spire Global shares fe...
This article discusses the upcoming events in the financial world, including the Federal Reserve meeting, corporate earnings, IPOs, and investor events.
